Keywords
leukemia
lymphoma
neurotoxicity
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To define the clinical picture of neurological events associated with CAR-T cell therapy and which approaches are effective for control, in order to ensure greater safety and to disseminate its use as a prototype for future treatments of solid and brain tumors. Methods: This article was an integrative review of controlled clinical trials, whose data were collected in the virtual databases: Medline and PubMed, in the period from April to May 2024. Results: Of the 35 articles selected, only 3 did not report the presence of neurological effects with the use of CAR-T cell therapy. Furthermore, most patients who underwent the therapy had complete remission, emphasizing the therapeutic efficacy against severe and refractory hematological cancers. Final considerations: The literature provides a divergent conclusion, without stating whether administration of smaller doses or the overall activity of the CAR-T product can vary the level of toxicity. However, there is no doubt that impairment of consciousness and focal deficit were evident in many cases after infusion of modified T cells, with most being treatable only with symptomatic treatment.
References
BELIN C, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Scientific Reports, 2020;10(1):18997.
OTTAVIANO G, et al. Phase 1 clinical trial of CRISPR-engineered CAR19universal T cells for treatment of children with refractory B cell leukemia. Science Translational Medicine, 2022;14(668).
BERDEJA JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed orrefractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.The Lancet, 2021;398(10297):314–24.
YING Z, et al. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Medicine, 2021;10(3):999–1011.
SAN-MIGUEL J, et al. Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma. New England Journal of Medicine, 2023.
YING Z, et al. Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study. Cytotherapy, 2023;25(5):521–9.
RODRIGUEZ-OTRO P, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2023;388(11):1002–14.
BENJAMIN R, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet, 2020;396(10266):1885–94.
LEI W, et al. Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discovery, 2024;10(1):1–14.
LEE L, et al. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. Journal for ImmunoTherapy of Cancer; 2023; 11(6): e006699–9.
SCORDO M, et al. Identifying an optimal fludarabine exposure for improved out-comes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Advances; 2023; 7(18): 5579–85.
LOPEDOTE P, Shadman M. Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab. Cancer Management and Research; 2023; 15:257-264.
XU J, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc. Natl. Acad. Sci. U.S.A., 2019;116 (19) 9543-9551.
FRIGAULT M, et al. Dose fractionation of CAR-T cells. A systematic review of clinical outcomes; 2023; 42(1):11.
WUDHIKARN K, et al. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Advances; 2023; 7(13): 3192–8.
SCHROEDER BA, et al. Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions. Current Opinion in Hematology, 2022; 29 (4): 225-232.
SUN Z, Liu M. Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma. Cytotherapy; 2022; 24(9): 940-953.
SHI X, et al. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. American Journal of Hematology; 2022; 1; 97(5): 537–47.
WANG S, et al. Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study. Frontiers in Pediatrics, 2023; 10.
RAM R, et al. Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients – a matched control multi-center cohort study. Haematologica, 2021.
RODDIE C,et al. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2021; 39(30):3352–63.
FOSTER MC, et al. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity. Blood, 2021;137(23):3306–9.
WEINSTEIN B, et al. Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtageneciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review. INNOVATIONS in pharmacy, 2021; 12(4):18.
ORTÍZ-MALDONADO V, et al. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies. Molecular Therapy, 2021;29(2):636–44
YAN ZX, et al. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin’s Lymphoma. Clinical Cancer Research, 2019; 25(23):6995–7003.
WANG M, et al. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. Journal for ImmunoTherapy of Cancer, 2020;8(2):e001114.
SHAH NN, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine, 2020; 26(10):1569–75.
CHITADZ G, et al. Bispecific antibodies in acute lymphoblastic leukemia therapy. Expert review of hematology, 2020; 13(11):1211–33.
MAGNANI CF, et al. Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. The Journal of Clinical Investigation, 2020;130(11):6021–33.
KERSTEN MJ, et al. CD19-directed CAR T-cell therapy in B-cell NHL. Current Opinion in Oncology, 2020; 32(5):408–17.